First-Line Treatment of Metastatic Gastrointestinal Stromal Tumor with KIT or PDGFRA Mutation
This protocol addresses metastatic gastrointestinal stromal tumor (GIST) confirmed to carry a
KIT or PDGFRA mutation, specifically in patients whose tumour does not
harbour a KIT exon 9 mutation and does not carry a PDGFRA D842V mutation.
Molecular genotyping is required to place patients correctly within this subpopulation.
Clinical Scenario
The defining feature of this subpopulation is its mutation profile: KIT or PDGFRA driver
mutation is present, with KIT exon 9 and PDGFRA D842V variants explicitly excluded.
Genotyping of advanced or metastatic GIST is mandatory before treatment selection.
Treatment Approach (partial)
First-line management in this genotype-defined subgroup involves an oral targeted therapy —
imatinib — continued based on response and tolerability. Full dosing, schedule, and criteria
for continuation are detailed in the complete protocol.
References
DOI: 10.1177/17588359231192388
- Genotype is mandatory for treating advanced/metastatic GIST patients (II,A).
- Imatinib 400 mg daily is the recommended dose in the first line (I,A).
- Consequently, imatinib must be continued until disease progression or until unacceptable toxicity (I,A).
View source ↗